{
  "normalized_facts": [
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "major depressive disorder",
        "relation": "TREATS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report",
        "span": "A total of 2,876 adult outpatients with major depressive disorder, enrolled from 18 primary and 23 psychiatric care sites, received citalopram in Level 1 of STAR*D. Treatment could last up to 14 weeks in each level.",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "STAR*D study",
        "sample_size": 2876,
        "duration": "up to 14 weeks",
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "TREATS",
        "concept_id": "CUSTOM:0001",
        "label": "TREATS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "depression",
        "relation": "IMPROVES",
        "outcome": "remission",
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Intervention",
        "span": "The aim of citalopram treatment in Level 1 was to achieve symptom remission, which was defined as QIDS-C score \u2264 5. The protocol required a fully adequate dose of citalopram for a sufficient time to maximize the likelihood of achieving remission.",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": null,
        "duration": null,
        "dose": "20-60 mg/day",
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "depression",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "relation": {
        "text": "IMPROVES",
        "concept_id": "CUSTOM:0002",
        "label": "IMPROVES",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": {
        "text": "remission",
        "concept_id": "SNOMED:277022003",
        "label": "Remission phase",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "depression",
        "relation": "EFFECTIVE_IN_SUBGROUP",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Intervention",
        "span": "TABLE 1. Treatment Characteristics of Patients in Level 1 of STAR*D, by Presence of Anxious Depression. Maximum citalopram dosage (mg/day) was \u2265 50 in 42.3% of patients without anxious depression and 44.6% with anxious depression.",
        "confidence": 0.8,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "observational",
        "sample_size": 2876,
        "duration": null,
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "depression",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "relation": {
        "text": "EFFECTIVE_IN_SUBGROUP",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "depression",
        "relation": "ASSOCIATED_WITH_SE",
        "outcome": null,
        "side_effects": [
          "greater frequency, intensity, and burden of side effects",
          "more serious adverse events"
        ],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Tolerability and Side Effects in Level 1, by Anxious Versus Nonanxious Depression",
        "span": "Despite similar citalopram dosages in the two groups and the longer treatment exposure in the nonanxious depression group (Table 1), the anxious depression group had greater a frequency, intensity, and burden of side effects than the nonanxious depression group, as well as more serious adverse events (Table 4).",
        "confidence": 0.8,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": null,
        "sample_size": null,
        "duration": null,
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "depression",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "relation": {
        "text": "ASSOCIATED_WITH_SE",
        "concept_id": "CUSTOM:0003",
        "label": "ASSOCIATED_WITH_SE",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [
        {
          "text": "greater frequency, intensity, and burden of side effects",
          "concept_id": null,
          "label": null,
          "provider": null,
          "match_type": "unmatched",
          "score": 0.0
        },
        {
          "text": "more serious adverse events",
          "concept_id": null,
          "label": null,
          "provider": null,
          "match_type": "unmatched",
          "score": 0.0
        }
      ],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "sustained-release bupropion",
        "condition_name": "major depressive disorder",
        "relation": "AUGMENTS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Sample Description of Level 2 Study Participants",
        "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to continue taking citalopram and receive augmentation with sustained-release bupropion (at a dose of up to 400 mg per day; N=279).",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": 279,
        "duration": null,
        "dose": "up to 400 mg per day",
        "p_value": null
      },
      "drug": {
        "text": "sustained-release bupropion",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "AUGMENTS",
        "concept_id": "CUSTOM:0004",
        "label": "AUGMENTS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "buspirone",
        "condition_name": "major depressive disorder",
        "relation": "AUGMENTS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Sample Description of Level 2 Study Participants",
        "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to continue taking citalopram and receive augmentation with buspirone (at a dose of up to 60 mg per day; N=286).",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": 286,
        "duration": null,
        "dose": "up to 60 mg per day",
        "p_value": null
      },
      "drug": {
        "text": "buspirone",
        "concept_id": "RXNORM:1827",
        "label": "Buspirone",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "AUGMENTS",
        "concept_id": "CUSTOM:0004",
        "label": "AUGMENTS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "sustained-release bupropion",
        "condition_name": "major depressive disorder",
        "relation": "TREATS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Sample Description of Level 2 Study Participants",
        "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to sustained-release bupropion (at a maximal daily dose of 400 mg; N=239).",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": 239,
        "duration": null,
        "dose": "maximal daily dose of 400 mg",
        "p_value": null
      },
      "drug": {
        "text": "sustained-release bupropion",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "TREATS",
        "concept_id": "CUSTOM:0001",
        "label": "TREATS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "sertraline",
        "condition_name": "major depressive disorder",
        "relation": "TREATS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Sample Description of Level 2 Study Participants",
        "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to sertraline (at a maximal daily dose of 200 mg; N=238).",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": 238,
        "duration": null,
        "dose": "maximal daily dose of 200 mg",
        "p_value": null
      },
      "drug": {
        "text": "sertraline",
        "concept_id": "RXNORM:3640",
        "label": "Sertraline",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "TREATS",
        "concept_id": "CUSTOM:0001",
        "label": "TREATS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "extended-release venlafaxine",
        "condition_name": "major depressive disorder",
        "relation": "TREATS",
        "outcome": null,
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Sample Description of Level 2 Study Participants",
        "span": "In Level 2 of STAR*D, 1,292 adult outpatients with major depressive disorder who had no remission of symptoms in Level 1 or could not tolerate citalopram were randomly assigned to switch to extended-release venlafaxine (at a maximal daily dose of 375 mg; N=250).",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "RCT",
        "sample_size": 250,
        "duration": null,
        "dose": "maximal daily dose of 375 mg",
        "p_value": null
      },
      "drug": {
        "text": "extended-release venlafaxine",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "TREATS",
        "concept_id": "CUSTOM:0001",
        "label": "TREATS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": null,
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "depression",
        "relation": "IMPROVES",
        "outcome": "remission",
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "discussion",
        "span": "In Level 1 of STAR*D, patients with anxious depression were less likely to respond or to remit with citalopram treatment than those with nonanxious depression. Overall, they also took longer to remit.",
        "confidence": 0.9,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "STAR*D Level 1",
        "sample_size": 2876,
        "duration": null,
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "depression",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "relation": {
        "text": "IMPROVES",
        "concept_id": "CUSTOM:0002",
        "label": "IMPROVES",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": {
        "text": "remission",
        "concept_id": "SNOMED:277022003",
        "label": "Remission phase",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "citalopram",
        "condition_name": "major depressive disorder",
        "relation": "MAINTENANCE_FOR",
        "outcome": "remission",
        "side_effects": [
          "worsening insomnia",
          "nervousness",
          "dryness of mouth",
          "constipation"
        ],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Patient Perspective",
        "span": "After 6 weeks of combined treatment with citalopram and a benzodiazepine, Ms. D reported a significant improvement in all her symptoms, and remission was achieved at the end of the 10th week of treatment. When the benzodiazepine dosage was decreased soon after remission had been achieved, Ms. D reported a reemergence of her insomnia and agitation. She and her physician agreed that she would maintain the treatment combination for at least 6 months.",
        "confidence": 0.7,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "case report",
        "sample_size": null,
        "duration": "10 weeks",
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "citalopram",
        "concept_id": "RXNORM:2556",
        "label": "Citalopram",
        "provider": "rxnorm",
        "match_type": "exact",
        "score": 1.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "MAINTENANCE_FOR",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "outcome": {
        "text": "remission",
        "concept_id": "SNOMED:277022003",
        "label": "Remission phase",
        "provider": "snomed",
        "match_type": "synonym",
        "score": 1.0
      },
      "side_effects": [
        {
          "text": "worsening insomnia",
          "concept_id": "SNOMED:193462001",
          "label": "Insomnia",
          "provider": "snomed",
          "match_type": "synonym",
          "score": 1.0
        },
        {
          "text": "nervousness",
          "concept_id": "SNOMED:48694002",
          "label": "Anxiety",
          "provider": "snomed",
          "match_type": "synonym",
          "score": 1.0
        },
        {
          "text": "dryness of mouth",
          "concept_id": "SNOMED:87715008",
          "label": "Xerostomia",
          "provider": "snomed",
          "match_type": "synonym",
          "score": 1.0
        },
        {
          "text": "constipation",
          "concept_id": "SNOMED:14760008",
          "label": "Constipation",
          "provider": "snomed",
          "match_type": "exact",
          "score": 1.0
        }
      ],
      "effect_size": null,
      "confidence_interval": null
    },
    {
      "raw_fact": {
        "drug_name": "benzodiazepine",
        "condition_name": "major depressive disorder",
        "relation": "AUGMENTS",
        "outcome": "improvement in insomnia and agitation",
        "side_effects": [],
        "effect_size": null,
        "confidence_interval": null,
        "source_id": "Psychiatry",
        "section": "Patient Perspective",
        "span": "Ms. D's anxiety escalated over the next few days, and a benzodiazepine was prescribed, which brought about a significant improvement in her insomnia and agitation.",
        "confidence": 0.7,
        "treatment_line": null,
        "patient_subgroup": null,
        "study_design": "case report",
        "sample_size": null,
        "duration": "6 weeks",
        "dose": null,
        "p_value": null
      },
      "drug": {
        "text": "benzodiazepine",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "condition": {
        "text": "major depressive disorder",
        "concept_id": "SNOMED:35489007",
        "label": "Major depressive disorder",
        "provider": "snomed",
        "match_type": "exact",
        "score": 1.0
      },
      "relation": {
        "text": "AUGMENTS",
        "concept_id": "CUSTOM:0004",
        "label": "AUGMENTS",
        "provider": "custom",
        "match_type": "exact",
        "score": 1.0
      },
      "outcome": {
        "text": "improvement in insomnia and agitation",
        "concept_id": null,
        "label": null,
        "provider": null,
        "match_type": "unmatched",
        "score": 0.0
      },
      "side_effects": [],
      "effect_size": null,
      "confidence_interval": null
    }
  ]
}